|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Our goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. Our near-term focus is to develop our product candidate, which we refer to as RVT-101, for the treatment of Alzheimer's disease and other forms of dementia. In the long-term, we intend to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
7 |
Founded: |
2014 |
|
| Contact Information |
| Address: |
Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -21.0 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
AXON |
| Shares (millions): |
21.0 |
| Price Range: |
$15.00 - $15.00 |
| Est.$ Volume |
$ 315.0 mil |
| Manager / Joint Managers |
Jefferies/ Evercore ISI/ RBC Capital Markets |
| Co Managers |
JMP Securities/ Baird |
| Expected to Trade |
6/11/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
